DK1501936T3 - Familie af cytokin-proteiner - Google Patents

Familie af cytokin-proteiner

Info

Publication number
DK1501936T3
DK1501936T3 DK02764322T DK02764322T DK1501936T3 DK 1501936 T3 DK1501936 T3 DK 1501936T3 DK 02764322 T DK02764322 T DK 02764322T DK 02764322 T DK02764322 T DK 02764322T DK 1501936 T3 DK1501936 T3 DK 1501936T3
Authority
DK
Denmark
Prior art keywords
family
cytokine proteins
amino acid
seq
acid residues
Prior art date
Application number
DK02764322T
Other languages
English (en)
Inventor
Brain A Fox
Paul O Sheppard
Kevin M Klucher
David W Taft
Wayne R Kindsvogel
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/895,834 external-priority patent/US6927040B2/en
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK1501936T3 publication Critical patent/DK1501936T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
DK02764322T 2001-04-20 2002-04-19 Familie af cytokin-proteiner DK1501936T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US28540801P 2001-04-20 2001-04-20
US28542401P 2001-04-20 2001-04-20
US28648201P 2001-04-25 2001-04-25
US09/895,834 US6927040B2 (en) 2000-06-30 2001-06-29 Interferon-like protein Zcyto21
US34105001P 2001-10-22 2001-10-22
US34110501P 2001-10-22 2001-10-22
PCT/US2002/012887 WO2002086087A2 (en) 2001-04-20 2002-04-19 Cytokine protein family

Publications (1)

Publication Number Publication Date
DK1501936T3 true DK1501936T3 (da) 2008-12-08

Family

ID=27559579

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02764322T DK1501936T3 (da) 2001-04-20 2002-04-19 Familie af cytokin-proteiner

Country Status (12)

Country Link
EP (2) EP1501936B1 (da)
JP (1) JP4350950B2 (da)
CN (2) CN101531715A (da)
AT (2) ATE403726T1 (da)
AU (1) AU2002307510A1 (da)
BR (1) BR0205083A (da)
CA (1) CA2441958C (da)
DE (2) DE60237791D1 (da)
DK (1) DK1501936T3 (da)
ES (1) ES2311622T3 (da)
RU (1) RU2321594C2 (da)
WO (1) WO2002086087A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334888T3 (es) * 2000-11-28 2010-03-17 Zymogenetics, L.L.C. Receptor de citocina zcytor19.
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
EP1497415B1 (en) * 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methods for detection or modulation of the interaction of a cytokine receptor with its ligand
WO2004037995A2 (en) * 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
ATE388963T1 (de) 2003-08-07 2008-03-15 Zymogenetics Inc Homogene herstellungen von il-29
WO2005097165A2 (en) 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
WO2006012644A2 (en) * 2004-07-29 2006-02-02 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer
JP4987001B2 (ja) * 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法
BRPI0817026A2 (pt) 2007-09-20 2017-05-16 Australian Poultry Crc Pty Ltd molécula de ácido nucleico, polipeptídeo isolado, polipeptídeo de fusão, construção genética, métodos para produzir uma molécula de interferon-lambda recombinante aviário em uma célula, para identificar uma sequência genética de interferon-lambda aviário, para induzir ou regular de modo positivo uma resposta imune em aves e para o tratamento ou profilaxia de aves, molécula de interferon-lambda recombinante aviário, célula isolada, molécula de anticorpo, meio legível por computador, ensaio para mdir o nível de um polipeptídeo de interferon-lambda aviário em aves, uso do polipeptídeo de interferon-lambda aviário ou de uma molécula de ácido nucleico, gênero alimentício medicinal ou terapêutico, adjuvante, e, composição farmacêutica veterinária.
JP5821198B2 (ja) * 2011-01-27 2015-11-24 富士レビオ株式会社 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法
FR2975185A1 (fr) * 2011-05-12 2012-11-16 Univ Claude Bernard Lyon Procede de determination in vitro de la presence d'une sclerose en plaques
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
CN110894525A (zh) * 2018-09-12 2020-03-20 贵州大学 从江香猪IFN-λ1基因的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES498343A0 (es) * 1980-01-08 1983-09-01 Biogen Nv Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
CA2288360A1 (en) * 1997-04-25 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like factor 7
US5924404A (en) 1997-10-24 1999-07-20 Brunswick Corporation Cylinder-specific spark ignition control system for direct fuel injected two-stroke engine
EP1131333B1 (en) 1998-10-26 2010-06-02 Wyeth a Corporation of the State of Delaware ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
AU2157000A (en) 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
AU3891600A (en) * 1999-03-18 2000-10-04 Zymogenetics Inc. Murine interferon-alpha named also zcyto13
US6391948B1 (en) 1999-12-14 2002-05-21 3M Innovative Properties Company Triazine compounds and use thereof
CA2446180A1 (en) * 2001-05-10 2002-11-21 Immunex Corporation Cytokine polypeptides
AU2003215136A1 (en) * 2002-02-08 2003-09-02 University Of Medicine And Dentistry Of New Jersey Ifn-a/b-independent mechanism of antiviral protection

Also Published As

Publication number Publication date
WO2002086087A3 (en) 2004-11-18
ATE482272T1 (de) 2010-10-15
DE60237791D1 (de) 2010-11-04
RU2321594C2 (ru) 2008-04-10
CA2441958A1 (en) 2002-10-31
CN100482684C (zh) 2009-04-29
ATE403726T1 (de) 2008-08-15
JP4350950B2 (ja) 2009-10-28
DE60228136D1 (de) 2008-09-18
CN101531715A (zh) 2009-09-16
WO2002086087A2 (en) 2002-10-31
EP1942187A1 (en) 2008-07-09
CA2441958C (en) 2012-01-17
CN1620510A (zh) 2005-05-25
BR0205083A (pt) 2004-07-20
AU2002307510A1 (en) 2002-11-05
EP1501936B1 (en) 2008-08-06
RU2003133748A (ru) 2005-05-10
EP1942187B1 (en) 2010-09-22
JP2005506052A (ja) 2005-03-03
EP1501936A2 (en) 2005-02-02
ES2311622T3 (es) 2009-02-16
EP1501936A4 (en) 2005-07-20

Similar Documents

Publication Publication Date Title
CY1112833T1 (el) Καινοφανης προσδετης της κυτοκινης ζcυτοr17
DK1501936T3 (da) Familie af cytokin-proteiner
DK0839196T3 (da) Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner
ATE390441T1 (de) Niedrigallergene proteinvarianten
DK1717316T3 (da) Allelisk variant af interferon-lignende protein Zcyto21
ATE495247T1 (de) Chromoprotein und fluoroproteine
NO971508L (no) Analoger av sur fibroblastvekstfaktor med forökt stabilitet og biologisk aktivitet
DK1077068T3 (da) Anvendelse af interferon alfa 5 i behandlingen af virale hepatopatier
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DK1425295T3 (da) Modificerede peptider og deres anvendelse til behandling af autoimmune sygdomme
DK0828004T3 (da) Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
DE60135971D1 (de) Mit wt1 interagierendes protein, wtip